MUC16 and pancreatic ductal adenocarcinoma: Long-term survivors of pancreatic ductal adenocarcinoma (PDAC) are enriched in MUC16/CA125 neoantigens, suggesting that MUC16 may serve as a candidate immunogenic hotspot in PDAC [56].